Levobupivacaína Altan

Levobupivacaine, the active ingredient in Levobupivacaína Altan, is a local anesthetic (amide) presented as a sterile solution for epidural, infiltration, intrathecal and peripheral nerve block use. It provides reversible loss of sensation for surgical anesthesia, postoperative and labor analgesia, and targeted nerve block procedures.

GNH USA supplies Levobupivacaína Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levobupivacaine is employed in the management of pain and anesthesia across several clinical pathways. - Surgical anesthesia: produces complete loss of sensation during operative procedures. - Post‑operative analgesia: extends pain relief after surgery to improve recovery. - Labor analgesia: reduces uterine contraction pain while preserving maternal consciousness. - Peripheral nerve blocks for acute or chronic pain: enables targeted analgesia for limb surgeries or chronic pain syndromes.

Levobupivacaína Altan may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure after administration. - Bradycardia: slowed heart rate, especially with high spinal or epidural doses. - Dizziness or light‑headedness. - Nausea or vomiting. - Metallic taste or oral paraesthesia. - Injection‑site pain or erythema.

Serious or Rare Side Effects: - Cardiovascular toxicity: arrhythmias, cardiac arrest, or severe hypotension. - Central nervous system toxicity: seizures, convulsions, or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis. - Respiratory depression or apnea. - Prolonged motor block. - Persistent neurologic deficits.

Levobupivacaína Altan requires careful clinical assessment and monitoring before and during use. - Cardiac assessment: evaluate baseline heart function and monitor ECG during administration. - Hemodynamic monitoring: observe blood pressure and heart rate for signs of hypotension or bradycardia. - Incremental dosing: use fractionated doses to reduce risk of systemic toxicity. - Hypersensitivity: avoid in patients with known allergy to amide‑type local anesthetics. - Hepatic impairment: adjust dose or avoid if severe liver disease is present. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Levobupivacaína Altan can interact with other drugs that affect cardiac or central nervous system function.

Major Interactions (Avoid): - Other local anesthetics: cumulative toxicity may occur. - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiotoxicity. - Beta‑blockers: may enhance bradycardia and hypotension. - Calcium channel blockers: can potentiate hypotensive effects. - Central nervous system depressants: heightened risk of CNS toxicity.

Moderate Interactions (Monitor Closely): - Opioids: additive sedation and respiratory depression. - Benzodiazepines: increased CNS depression. - Monoamine oxidase inhibitors: potential for hypertensive episodes.